Watch for continued execution on the Medical-Surgical spin-off and synergy from the Apollo partnership. The raised guidance signals confidence in sustained 12-14% EPS growth, which could drive further multiple expansion. Monitor the Q1 FY2027 call for progress on segment separation.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 8 $732.70entry
- T+1 · 6mo ago −1.10%α −1.33% · $724.62
- T+5 · 6mo ago +1.98%α +0.52% · $747.23
- T+20 · 5mo ago +5.86%α +5.84% · $775.66
- T+60 · 3mo ago +12.89%α +10.17% · $827.14
Price Chart
How similar events traded
Executive Summary
McKesson reported a strong Q4 FY2026 with GAAP EPS of $13.71 (+37% YoY) and Adjusted EPS of $11.69 (+16% YoY) on revenue of $96.3B (+6% YoY). Full year Adjusted EPS grew 18% to $39.11, above long-term targets. The company raised FY2027 Adjusted EPS guidance to $43.80-$44.60 (12-14% growth), announced a $5B share repurchase increase, and signed a deal for Apollo Global to acquire a 13% minority stake in its Medical-Surgical segment.
Key Financial Metrics
Key Facts
- Q4 FY2026 GAAP EPS $13.71 (up 37% YoY), Adjusted EPS $11.69 (up 16% YoY)
- Q4 revenue $96.3B (up 6% YoY), full year revenue $403.4B (up 12% YoY)
- FY2027 Adjusted EPS guidance $43.80-$44.60 (12-14% growth)
- $5.0B increase to share repurchase authorization, total $7.7B; $2.25B ASR completed in Q4
- Apollo Global to acquire ~13% minority stake in Medical-Surgical segment
- Cash flow from operations $3.4B and Free Cash Flow $3.2B in Q4
Financial Impact
Strong earnings beat with 16% adjusted EPS growth, raised guidance, and significant capital return
Risk Factors
- Opioid litigation remains a long-term overhang with $5.1B in long-term litigation liabilities
- Execution risk on Medical-Surgical separation and minority stake closing
- Potential headwinds from branded pharmaceutical pricing pressure
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000927653-26-000066 |
| Document: mck-20260507.htm | 0000927653-26-000066 |
| Document: 0000927653-26-000066-index-headers.html | 0000927653-26-000066 |
| Document: 0000927653-26-000066-index.html | 0000927653-26-000066 |
| Document: 0000927653-26-000066.txt | 0000927653-26-000066 |
| 8-K Data (Synthetic) | 0000927653-26-000066 |
Track record
26 reports on MCK
4 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +22.92% at T+60 after the Apr 1, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 5, 202612d ago 144 Neutral 2/10 Entry $1,072.00 to $1,077.05 Now $1,091.52 +1.82% ▲ +0.47% −2.82% vs SPY
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $1,072.00 to $1,077.05 Now $1,091.52 +1.82% ▲ +0.47% −2.82% vs SPY
- Nov 4, 202613d ago 8-K Bullish 6/10 Entry $1,072.00 to $1,077.05 Now $1,091.52 +1.82% ▲ +0.47% −2.82% vs SPY
- Oct 30, 202618d ago 25-NSE Neutral 1/10 Entry $994.58 to $1,060.84 Now $1,091.52 +9.75% ▲ +6.66% +9.37% vs SPY
- Oct 28, 202620d ago Institutional Cluster Neutral 3/10 Entry $960.56 to $1,069.44 Now $1,091.52 +13.63% ▲ +11.34% +12.05% vs SPY
- Oct 27, 202621d ago GOVT-CONTRACT Neutral 3/10 Entry $960.56 to $1,069.44 Now $1,091.52 +13.63% ▲ +11.34% +12.05% vs SPY
- Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $955.76 to $1,010.43 Now $1,091.52 +14.20% ▲ +5.72% +7.21% vs SPY
- Oct 6, 20266w ago 8-K Bullish 6/10 Entry $921.67 to $961.88 Now $1,091.52 +18.43% ▲ +4.36% +4.50% vs SPY
- Sep 1, 202611w ago GOVT-CONTRACT Neutral 3/10 Entry $924.78 to $880.86 Now $1,091.52 +18.03% ▼ −4.75% −3.79% vs SPY
- Aug 28, 202611w ago 8-K Neutral 4/10 Entry $885.32 to $896.29 Now $1,091.52 +23.29% ▲ +1.24% +1.38% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers